For example, there is a growing body of literature describing the ability of PAR1 and PAR2 to transactivate the EGFR in cells from several carcinomas including lung [69], kidney [111], colon [112-115] and gastric cancer [116,117]. The gene discussed is MARK2; the disease is carcinoma.